Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Empagliflozin in Patients with Metabolic Dysfunction-Associated Liver Disease
IRCT20260510069334N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Shahid Beheshti University of Medical Sciences. Started May 2026; status: completed.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20260510069334N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260510069334N1.